NCT01659086 - Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age | Biotech Hunter

Enrollment

422

Participants

Timeline

Start Date

August 22, 2012

Primary Completion Date

October 26, 2012

Study Completion Date

March 19, 2014

Conditions

Influenza

Interventions

BIOLOGICAL

Investigational H9N2 vaccine GSK2654911A

2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.

BIOLOGICAL

Investigational H9N2 vaccine GSK2654909A

2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.

BIOLOGICAL

Placebo

1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.

Trial Locations (4)

33143

GSK Investigational Site, Miami

78705

GSK Investigational Site, Austin

08817

GSK Investigational Site, Edison

J1H 2G2

GSK Investigational Site, Sherbrooke